Brief: GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
04/01/2024 12:37
Jan 4 (Reuters) - GlycoMimetics Inc GLYC.O :
* GLYCOMIMETICS INC - GMI-1687, MET ITS PRIMARY AND
SECONDARY
ENDPOINTS WITH NO DOSE-LIMITING TOXICITIES OR SAFETY SIGNALS
Source text for Eikon: ID:nBw3Ft3YLa
Further company coverage: GLYC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering